Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-204 Open-Label Extension in Alzheimer's Disease Psychosis
NCT06194799Phase 3Enrolling by invitation
- Sponsor
- Acadia Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of remlifanserin in Alzheimer's disease (AD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events at 52 weeks. Started Apr 2024; status: enrolling by invitation.
02
Drugs
remlifanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06194799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194799.